SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
MNPR reported Third Quarter 2026 results. The price and volatility reaction is pending.
MNPRearnings

Earnings reactions, page 3

Monopar Therapeutics Inc. (MNPR) Q3 FY2026 earnings

November 12, 2026 · SharpeIQ Research Desk

Reported results

  • Net loss for the third quarter of 2026 was $6.2 million, or $0.72 per share.
  • Cash, cash equivalents and investments as of September 30, 2026, were $129.4 million.
  • R&D expenses for the third quarter of 2026 were $4,436,543.
  • G&A expenses for the third quarter of 2026 were $3,031,302.
  • Interest income for the third quarter of 2026 was $1,271,370.

Guidance

  • Monopar expects its current funds to support operations through at least March 31, 2028.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →